WILMINGTON, Del.–(BUSINESS WIRE)—- $INCY–Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa
WILMINGTON, Del.–(BUSINESS WIRE)—- $INCY–Povofortay® (povorcitinib) Approved in Europe as the First Once-Daily Oral Treatment for Adults with Moderate to Severe Hidradenitis Suppurativa